Ranbaxy to conduct research with DBT in area of TB

New Delhi, Apr 9 (UNI) Pharmaceutical major Ranbaxy Laboratories Ltd today said it has entered into an agreement with Department of Biotechnology (DBT) of the government to conduct research in tuberculosis.

Three major areas identified in this New Drug Discovery Research (NDDR) are development of diagnostics, vaccines and drugs under the public-private partnership, a company statement said.

Under the alliance, Ranbaxy will develop novel drugs, using inhibitor design for novel targets/pathways /proteins among others.

DBT will support the project with a financial grant for a period of three years in the first phase of the collaboration.

''We are pleased to have this alliance with DBT, under Science and Technology Ministry, in the area of NDDR and will work towards building a winning model to develop innovative medicines in the area of tuberculosis,'' company CEO and MD Malvinder Mohan Singh said.

UNI SG MP AS1410